espite being preventable and curable, tuberculosis (TB) is the world’s deadliest infectious disease, killing 1.6 million people every year—more than HIV/AIDS and malaria combined. Underserved communities bear the largest burden, with more than 95% of TB-related deaths occurring in low- and middle-income countries, but this airborne disease knows no borders.

              Growing drug resistance is compounding this public health challenge. In 2017, there were nearly 500,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most frequently used first-line TB drugs. Drug-resistant TB now accounts for nearly one-third of all deaths from antimicrobial resistance (AMR).

              For nearly 20 years, both in our laboratories and on the ground in countries impacted by TB and MDR-TB, Johnson & Johnson has been supporting global efforts to end TB and combat AMR.

              Our Mission: Enabling a World Without TB
              Our Mission: Enabling a World Without TB
              In 2012, our medicine for pulmonary MDR-TB was granted accelerated approval by the United States Food and Drug Administration (U.S. FDA) for use as part of a combination therapy in adults when an effective treatment regimen cannot otherwise be provided. This was the first targeted TB drug with a novel mechanism of action to be approved in more than 40 years.

              Today, our TB medicine is approved in many countries around the world, including in many high-burden countries, and registration efforts are ongoing in several others. It is also available in dozens more countries procuring the medicine through the Stop TB Partnership’s Global Drug Facility.

              By the Numbers

              Courses of our medicine delivered to date
              Courses of our medicine provided for free through a four-year donation program
              Countries accessing our medicine, including the 30 highest-burden countries
              Countries in which our medicine has been approved

              Our 10-Year Initiative

              In September 2018, Johnson & Johnson reaffirmed its continued commitment to the fight against TB by announcing a new 10-year initiative with three pillars:

              • Expanding access to treatment by offering a not-for-profit price to 130+ low- and middle-income countries, as well as nongovernmental organizations, procuring our medicine through the Stop TB Partnership’s Global Drug Facility
              • Improving case finding and strengthening health systems to reach the thousands of people with undiagnosed TB and MDR-TB and connect them to care, including by improving diagnostic capacity, training health workers and raising community awareness
              • Accelerating TB research and development (R&D) to discover innovative next-generation treatments that will be needed to reach the global goal of ending TB

              Our Latest News

              Learn Why Now’s the Time to Act

              Pathway to Progress

              New Compound Is Identified

              Janssen investigates possible compound for the treatment of MDR-TB.

              Janssen’s MDR-TB Medicine Shows Promise

              Janssen team publishes study in Science showing new drug killed TB bacteria—including drug-resistant bacteria—in the test tube and in a mouse model at faster rate than existing TB drugs.

              Medicine Receives Accelerated FDA Approval

              Our MDR-TB medicine is granted accelerated approval by the U.S. FDA as the first targeted drug with a novel mechanism of action against TB in more than 40 years.

              Agreement Signed for Russia and CIS

              Our company enters into a commercial licensing agreement with JSC Pharmstandard for the registration, commercialization and manufacturing of MDR-TB medicine for Russia and several other countries in the region.

              Europe Grants Conditional Approval

              Following a positive opinion from the European Medicines Agency, the European Commission grants conditional approval of our medicine for MDR-TB.

              Johnson & Johnson Enters Collaboration With Global Drug Facility

              This partnership with a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) helps to facilitate access to the company’s MDR-TB medicine.

              Collaboration Announced to Further Evaluate Medicine

              Janssen announces collaboration with the International Union Against TB and Lung Disease (The Union) to include our MDR-TB medicine in two arms of the STREAM study, an ongoing trial to evaluate MDR-TB treatment regimens.

              Johnson & Johnson Launches Four-Year Donation Program

              Our company commits to provide up to 30,000 courses of our medicine, free of charge, in up to 110 eligible countries through a donation program with USAID and Pharmstandard (quantities later increased, see March 2019).

              MDR-TB Medicine Added to WHO Essential Medicines List

              The World Health Organization adds our MDR-TB medicine to its Essential Medicines List.

              Janssen Wins Prestigious International Award

              Our MDR-TB medicine receives an International Prix Galien Award, recognizing excellence in scientific innovation to improve human health.

              Johnson & Johnson Announces Extension of Donation Program

              In response to high demand, Johnson & Johnson commits to provide an additional 30,000 courses of treatment through its donation program with USAID and JSC Pharmstandard; ultimately donated 105,000 courses (see March 2019).

              South African Government Leads the Way

              South Africa becomes the first country to recommend a bedaquiline-containing, injection-free regimen for all eligible MDR-TB patients.

              Johnson & Johnson Offers Not-for-Profit Price to Eligible Countries

              Johnson & Johnson announced that our MDR-TB medicine would be made available at a not-for-profit price to more than 130 countries procuring our medicine through the Stop TB Partnership’s Global Drug Facility.

              New Study Suggests Cost-Effectiveness of Our MDR-TB Medicine

              A new cost-effectiveness study suggests both long- and short-course regimens containing our MDR-TB drug, without injectables, are cost-effective and provide significant health system savings.

              Johnson & Johnson Announces 10-Year TB Initiative

              Johnson & Johnson announces new 10-year TB initiative aimed at improving case finding, expanding treatment access and advancing R&D.

              WHO Finalizes New MDR-TB Treatment Guidelines

              The World Health Organization announces revised treatment guidelines for MDR-TB that categorize our medicine as a “Group A” medicine to be prioritized when constructing a conventional (long-course) regimen for MDR-TB.

              Conclusion of Successful Donation Program

              Johnson & Johnson ultimately committed 105,000 courses of our MDR-TB medicine, free of charge, to 80 countries through four-year donation program with USAID and JSC Pharmstandard.

              Johnson & Johnson-Supported EIU Report Launches

              Report estimates DR-TB deaths in a single year cost the global economy at least US$17.8 billion and calls for action to end the epidemic.

              Johnson & Johnson Launches New R&D Collaboration

              Johnson & Johnson partners with the EU’s Innovative Medicines Initiative and eight European academic and research institutions to launch a new collaboration aimed at accelerating the discovery of new TB medicines.

              January 2002

              January 2005

              December 2012

              January 2013

              March 2014

              April 2014

              November 2014

              April and December 2015

              May 2015

              December 2016

              May 2018

              June 2018

              July 2018

              August 2018

              September 2018

              March 2019

              March 2019

              May 2019

              July 2019

              Champions to #ENDTB

              To end TB, we urgently need to bring forward a new generation of treatments and multidrug regimens that are shorter, safer and more effective than many of the drugs currently used to treat the disease.

              At Johnson & Johnson, our top priority is developing and delivering medicines to all patients in need. We stand committed to working closely with countries and other partners to rapidly scale up access to bedaquiline and reach all eligible patients.

              Our mission has always been to ensure that patients have access to the best and most innovative TB treatment. I am confident that together with our global partners, we can achieve our ambitious goal of ending TB by 2030.

              It has been an honor to be part of the team that worked to develop the first novel medicine for patients with multidrug-resistant tuberculosis in the last 40 years. Our achievement highlights the importance of research to improve global public health and reinforces Johnson & Johnson’s commitment to Our Credo: patients come first.

              Innovative Research Around the World

              Report notes gaps in world’s response to drug-resistant TB
              Report offers annual assessments of TB epidemic.
              Plan provides five-year road map for the fight against TB.
              Led by the UN and KPMG to convert interest in Sustainable Development Goals into strategic activities.
              Examining role and definition of core and companion drugs.
              Study says newer drugs may have more robust efficacy data.
              Study says there is an expanding body of evidence on the events caused by these drugs.
              Study describes case detection and patient outcomes in a community-based program.
              Study finds link with faster conversion in patients with multidrug-resistant tuberculosis.
              Study found improved cure rates when added to multidrug-resistant treatment regimen.
              This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
              You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.